

Open End Turbo Call Warrant on Aryzta

SSPA Product Type: Warrant with Knock-Out (2200, Callable)
 Valor: 55507405 / ISIN: CH0555074050 / SIX Symbol: OAAYSU

Final Termsheet
 For marketing purposes only

Product & Underlying Information

Underlying(s)	Reference Level	Initial Strike / Knock-Out Barrier	Conversion Ratio
Aryzta AG Bloomberg: ARYN SE / LSEG: ARYN.S / Valor: 142568471 / ISIN: CH1425684714	CHF 0.42	CHF 16.40	1:0.0250 (1 unit(s) refers to 0 underlying(s))

Aryzta adjusted for Reverse Stock Split as of 06 May 2025.

Aryzta: Valoren, ISIN change as of 2025-05-06

The Open End Turbo Call Warrant allows investors to profit disproportionately from the upward (bullish) trend of the Underlying. The Open End Turbo Call Warrant moves approximately 1 unit of currency up, if the Underlying moves 1 unit of currency up and vice versa, taking into account the Conversion Ratio and the adjustments of the Strike / Knock-Out Barrier.

If the value of the Underlying at any time during the product life time lies at or below the Current Knock-Out Barrier, the Open End Turbo Call Warrant expires immediately and worthless. The risk of loss is limited to the invested capital.

The Current Knock-Out Barrier is always equal to the Current Strike.

Product Details

Security Numbers	Valor: 55507405 / ISIN: CH0555074050 / SIX Symbol: OAAYSU
Issue Size	Up to 167,000,000 units (with reopening clause)
Issue Price	CHF 0.06 (unit quotation)
Redemption Currency	CHF
Strike / Knock-Out Barrier Currency	CHF
Settlement	Cash settlement

Dates

Launch Date	09 July 2020
Fixing Date (Pricing)	09 July 2020
Initial Payment Date (Issue Date)	16 July 2020
First SIX Trading Date	10 July 2020
Valuation Date	Means the day when either the Investor's Exercise Right or the Issuer's Exercise Right becomes effective or the day a Knock-Out Event occurs.
Expiration Date (Expiry)	Open End (subject to the occurrence of a Knock-Out Event)
Maturity Date	Means the 3rd Banking Day following the Valuation Date.

Redemption

The Investor is entitled to receive from the Issuer an amount in the Redemption Currency, according to the following scenarios:

Scenario 1 (in case of Issuer Exercise or Investor Exercise)	If a Knock-Out Event has NOT occurred , the Investor will receive the Redemption Amount on the Maturity Date.
Scenario 2	If a Knock-Out Event has occurred , the Open End Turbo Warrant expires immediately and worthless.
Redemption Amount	Max [0, (Settlement Price - Current Strike)], considering the Conversion Ratio, converted into the Redemption Currency, if applicable.
Settlement Price	Official closing price of the Underlying on the Valuation Date, as reasonably determined on the Relevant Exchange.
Current Knock-Out Barrier	The Current Knock-Out Barrier equals the Current Strike.
Current Strike	<p>The Current Strike (S) will be determined by the Calculation Agent at its reasonable discretion on a daily basis commencing from the Initial Strike in accordance with below formula and rounded to four decimal places; it will be readjusted before market opening on a daily basis.</p> <p>The Current Strike will be available on www.ubs.com/keyinvest or any successor page.</p> $S_{\text{new}} = S_{\text{old}} + \frac{(R + FS) \cdot S_{\text{old}} \cdot n}{360} - \text{Dividend} \cdot \text{DivFactor}$ <p>S_{new} Current Strike after the adjustment.</p> <p>S_{old} Strike before the adjustment.</p> <p>Financing Spread (FS) Will be set between 0.5% and 15%, as determined by the Calculation Agent. The Initial Financing Spread is 3.5%.</p> <p>Rate (R) Means the SARON-Overnight-Rate as determined by the Calculation Agent at its reasonable discretion on the relevant adjustment date.</p> <p>Dividend (if applicable) Dividend or similar payments, as determined by the Calculation Agent at its reasonable discretion, distributed to the holders of the Underlying, whereby the ex-date of such payment on the Relevant Exchange is between the current and the next following Exchange Business Day.</p> <p>DivFactor (if applicable) The DivFactor may reflect any taxation applied on Dividends. The DivFactor is between 0 and 1 and is determined at the Calculation Agent's reasonable discretion.</p> <p>n Number of days between the current adjustment date (exclusive) and the next adjustment date (inclusive). The first current adjustment date equals the Launch Date.</p>
Knock-Out Event	<p>A Knock-Out Event shall be deemed to occur if at any time on any Exchange Business Day, starting on the Launch Date, the level of the Underlying as quoted by the Relevant Exchange is at or below the Current Knock-Out Barrier, as reasonably determined by the Calculation Agent.</p> <p>A Knock-Out Event will override both the Issuer Exercise Right and the Investor Exercise Right.</p>

General Information

Issuer	UBS AG, Zurich
Issuer Rating	Aa2 Moody's / A+ S&P / A+ Fitch
Issuer Supervisory Authority	Swiss Financial Market Supervisory Authority (FINMA). London Branch additionally Financial Conduct Authority (FCA) and Prudential Regulation Authority (PRA). Jersey Branch additionally Jersey Financial Services Commission (JFSC).
Lead Manager	UBS AG, Zurich (UBS Investment Bank)
Calculation Agent	UBS AG, Zurich
Paying Agent	UBS Switzerland AG

Relevant Exchange	Aryzta: SIX Swiss Exchange
Exchange Business Day	Exchange Business Day means each day, on which the Relevant Exchange is open for trading and the price of the Underlying is determined in accordance with the relevant rules.
Listing	SIX Swiss Exchange
Secondary Market	The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and/or offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and/or offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Daily price indications, if any, will be available on LSEG/Bloomberg, www.ubs.com/keyinvest and SIX Financial Information.
Issuer Exercise Right	<p>The Issuer has the right to terminate and redeem the Open End Turbo Warrant every 3 months, for the first time on 01 December 2020 ("Issuer Exercise Date"), for a value equal to the Redemption Amount (as described herein), subject to a period of notice of 3 month(s). In case that any of the dates is not an Exchange Business Day, the next following Exchange Business Day applies.</p> <p>The Open End Turbo Warrant will be redeemed on the Maturity Date.</p>
Investor Exercise Right	<p>In addition to the possibility to sell the Open End Turbo Warrant in the Secondary Market, each Investor has the right to exercise the Open End Turbo Warrant every 3 month(s), for the first time on 01 September 2020 ("Investors Notice Date") for a value equal to the Redemption Amount (as described herein), effective on the Investors Notice Date (Valuation Date).</p> <p>The notice has to be received no later than 10:00h, local time Zurich on the relevant Investors Notice Date, otherwise the notice will be effective as per the next following Investor Notice Date. The Investor Exercise will become effective as of close of business on the relevant Valuation Date. In case that any of the dates is not an Exchange Business Day, the next following Exchange Business Day applies.</p> <p>The Open End Turbo Warrant will be redeemed on the Maturity Date.</p>
Minimum Trading Lot	1 Open End Turbo Warrant(s)
Minimum Exercise	1 Open End Turbo Warrant(s), Open End Turbo Warrants may only be exercised in integral multiples of 1.
Clearing	SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)
Form of Deed	Uncertificated Securities
Status	Unsecured / Unsubordinated
Governing Law / Jurisdiction	Swiss / Zurich
Adjustments	The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation.
Public Offering	Switzerland

Important Information

The information herein is communicated by UBS AG and/or its affiliates ("**UBS**"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the Product to which this document relates. UBS may provide investment banking and/or other services to and/or have officers who serve as directors of the companies referred to in this document. UBS's trading and/or hedging activities related to this Product may have an impact on the price of the underlying asset(s) and may affect the likelihood that any relevant barrier(s) is/are crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price ("**Distribution Fees**"). Distribution Fees disclosed herein reflect the maximum amount a dealer or financial institution may receive from UBS; the actual amount may be lower. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisors you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial advisor or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment in the Product to which this document relates will be exclusively subject to the detailed provisions contained in the Product Documentation.

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for Investors that are not paid by UBS or imposed by it. Please refer to the Product Documentation for further information.

Product Documentation

The complete information regarding the Products, in particular the binding terms and conditions as well as the information regarding the Issuer along with the risk factors can be found in the respective Final Terms and the associated Base Prospectus, consisting of the Securities Note for the issuance of Warrants and other leveraged Securities and the related Registration Document of UBS AG, (including any supplements thereto) (together the "**Product Documentation**"). The Product Documentation and if available the Key Information Document, can be obtained free of charge from UBS AG, P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, for clients outside of the United Kingdom, the Product Documentation is available at www.ubs.com/keyinvest. Notices in connection with this Product shall be validly given by publication as described in the Product Documentation. Furthermore, for clients outside of the United Kingdom, any changes with regard to the terms of this Product shall be published at www.ubs.com/keyinvest.

Tax Treatment Switzerland

Swiss Transfer Stamp Duty	The product does not qualify as a taxable security. Transactions are not subject to Swiss Stamp Duty.
Swiss Income Tax	For private investors resident in Switzerland, an investment in this product is not subject to income tax.
Swiss Withholding Tax	This product is not subject to the Swiss Issuer Withholding Tax. It depends on the jurisdiction of the issuer whether a foreign issuer withholding tax applies.

The tax information only provides a general overview over the Swiss tax consequences linked to this product based on the tax laws and the practice of the tax administration at the time of issue. Tax laws and the practice of tax administrations may change, possibly with retroactive effect.

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below should not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

European Economic Area - In relation to each Member State of the European Economic Area (each, a "Member State"), an offer of the Products to the public in a Member State may only be made in accordance with the following exemptions as set out in the Regulation (EU) 2017/1129 (as may be amended or replaced from time to time) (the "Prospectus Regulation"):

- (a) Qualified investors: at any time to any legal entity which is a qualified investor as defined in the Prospectus Regulation;
- (b) Fewer than 150 offerees: at any time to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation);
- (c) An offer of Products addressed to investors who acquire Products for a total consideration of at least EUR 100,000 per investor, for each separate offer; and/or
- (d) Other exempt offers: at any time in any other circumstances falling within Article 1 (4) of the Prospectus Regulation, provided that no such offer of Products referred to in (a) to (d) above shall require the publication of a prospectus pursuant to Article 3 of the Prospectus Regulation, or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

For the purposes of this provision, the expression "offer of Securities to the public" in relation to any Products in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the Products to be offered so as to enable an investor to decide to purchase or subscribe the Products.

The aforementioned restrictions shall not apply for jurisdictions specified in the section "Public Offering" under "General Information" above.

Hong Kong - Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

Singapore - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Products may not be circulated or distributed, nor may the Products be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore, as modified and/or amended from time to time (the "SFA")) pursuant to Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where the Products are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Products pursuant to an offer made under Section 275 of the SFA except:

(1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(c)(ii) of the SFA;

(2) where no consideration is or will be given for the transfer;

(3) where the transfer is by operation of law;

(4) as specified in Section 276(7) of the SFA; or

(5) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.

Pursuant to section 309B(1)(c) of the SFA, UBS AG hereby notifies the relevant persons (as defined in the SFA) that the Products are classified as "*capital markets products other than prescribed capital markets products*" (as defined in the SFA and the Securities and Futures (Capital Markets Products) Regulations 2018) and "*Specified Investment Products*" (as defined in the MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

UK - An offer of the Products to the public in the United Kingdom may only be made in accordance with the following exemptions as set out in the UK Prospectus Regulation and/or FSMA (as applicable):

(a) Qualified investors: at any time to any person which is a qualified investor as defined in the UK Prospectus Regulation;

(b) Fewer than 150 offerees: at any time to fewer than 150 natural or legal persons (other than qualified investors as defined in the UK Prospectus Regulation);

(c) Other exempt offers: at any time in any other circumstances falling within section 86 of the FSMA,

provided that no such offer of Securities referred to in (a) to (c) above shall require the publication of a prospectus pursuant to section 85 of the FSMA, or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.

For the purposes of the forgoing provisions, the expression an "offer of Securities to the public" in relation to any Securities means the communication in any form and by any means of sufficient information on the terms of the offer and the Securities to be offered so as to enable an investor to decide to purchase or subscribe for the Securities; the expression "UK Prospectus Regulation" means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended) (the "EUWA"); and "FSMA" means the Financial Services and Markets Act 2000.

USA - This Product may not be sold or offered within the United States or to U.S. persons.